The application of next generation sequencing to the understanding of antibody repertoires

In the decade since the human genome sequence was declared complete, the development of next generation sequencing (NGS) or "deep" sequencing to deliver cost-effective genomic sequencing has influenced advances beyond its primary application and changed the research landscape in many other...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 4; p. 265
Main Authors Mathonet, Pascale, Ullman, Christopher G
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 11.09.2013
Subjects
antibody
antibodyome
Deep sequencing
Humoral Immune Response
Immunology
Next-generation sequencing
repertoire
antibody
deep sequencing
next generation sequencing
antibodyome
humoral immune response
repertoire
synthetic library
Online AccessGet full text

Cover

More Information
Summary:In the decade since the human genome sequence was declared complete, the development of next generation sequencing (NGS) or "deep" sequencing to deliver cost-effective genomic sequencing has influenced advances beyond its primary application and changed the research landscape in many other areas. This review will survey recent applications of NGS which have broadened the understanding of natural antibody repertoires (the "antibodyome") and how these evolve in response to viral infection. We will also report examples where deep sequencing of binding populations, derived from both natural and synthetic repertoires, have been used to benefit antibody engineering. This knowledge will ultimately lead to the design of more effective biological drugs and vaccines.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Reviewed by: Ramit Mehr, Bar-Ilan University, Israel; Nina Luning Prak, Trustees of the University of Pennsylvania, USA; Christophe Bonny, Bicycle Therapeutics Limited, UK
This article was submitted to B Cell Biology, a section of the journal Frontiers in Immunology.
Edited by: Peter Timmerman, Pepscan Therapeutics B.V., Netherlands
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2013.00265